Cigna Corporation

CI · NYSE · USD

Can specialty pharmacy growth and the flat-fee pharmacy model replace the profit lost from repriced large clients, or does pharmacy benefit profit keep shrinking through 2027?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Specialty pharmacy demand

    The bull case is that specialty pharmacy demand is growing faster than the rest of health care and that Cigna keeps adding hospitals and health systems as clients.

  • Raised earnings outlook

    Management has raised the earnings floor twice and kept its long-term growth target, which the bull side reads as proof the rest of the company can carry the pharmacy transition.

  • Flat-fee pharmacy model

    The bull side argues the flat-fee pharmacy model removes rebate conflicts, matches where regulators are heading, and should earn margins similar to today's contracts once built.

  • Cash flow and share count

    Cash flow is recurring and the share count keeps falling, so portfolio pruning and buybacks add to per-share profit without the company needing to borrow more.

Bear case

  • Pharmacy client repricing

    The bear case is that the largest pharmacy clients were renewed at permanently lower margins, so pharmacy profit keeps falling while the new model is being built.

  • Thin pharmacy margins

    Building the flat-fee model adds cost through next year, and operating margins are thin enough that small pricing changes move a large share of profit.

  • Medical cost trend

    Medical cost trend stays elevated and surprise-billing arbitration adds expense, while premiums are set a year ahead of the claims they have to pay.

  • Coverage cuts and exchange exit

    GLP-1 coverage is being pared back and the individual exchange business is being exited, which removes volume that had been supporting growth.

Bull and bear points

Growth & Execution

In short: Specialty pharmacy is growing fast, while pharmacy benefit profits fall as large contracts are repriced.

Bull · 2

  • Specialty pharmacy sits in a market management expects to approach $500 billion

    Management puts the specialty pharmacy market at roughly $500 billion with high single-digit growth, and about 40% of it is drugs given in hospitals and clinics, where Shields adds health-system clients.

    Q2 FY2026 call

  • Full-year earnings guidance has been raised twice since February

    In February management guided to at least $30.25 a share for 2026; by July it guided to at least $30.45, which suggests the specialty and health plan businesses are absorbing the pharmacy investments so far.

    Tone shiftQ4 FY2025 → Q2 FY2026
Bear · 2

  • Repriced large pharmacy clients drive most of the 2026 profit decline

    Management said renewals with Prime Therapeutics, Centene and the Department of Defense account for more than half of the pharmacy benefit profit drop, and that lower margin becomes the base through the end of the decade.

    Q3 FY2025 call

  • GLP-1 growth has slowed and coverage is being pared back

    Management once counted its GLP-1 programs as a growth driver; it now describes moderating prescription growth, slightly lower coverage, and has stopped paying for weight-loss GLP-1s in its own employee plan.

    Tone shiftQ3 FY2025 → Q2 FY2026

Profitability & Financial Strength

In short: Cash flow is strong and the share count falls, while thin margins and transition spending limit profit.

Bull · 2

  • Free cash flow more than doubled versus the prior twelve months

    Cash generation of $9.1 billion, about 3.2% of revenue, funds the pharmacy build-out, the dividend and buybacks without new borrowing.

    Filed financials

  • Buybacks and dividends are paid out of cash flow

    The company returned $2.9 billion to shareholders over the last twelve months, roughly a third of free cash flow, split between $1.3 billion of buybacks and $1.6 billion of dividends, and buybacks keep shrinking the share count.

    Filed financials
Bear · 2

  • Signature model spending stays at the same level in 2027

    Management told investors the transition cost is not a one-year item, so pharmacy benefit margins stay depressed for another year before any recovery.

    Q2 FY2026 call

  • A 3.7% operating margin leaves little room for pricing mistakes

    Because pharmacy revenue is booked at the full cost of the drug, a small change in fees, drug mix or client terms moves a large share of operating profit.

    Filed financials

Market Position

In short: High client retention and clearer regulation help, but drugmaker contracts can end on short notice.

Bull · 2

  • Client retention is high and 2027 new business beats recent seasons

    Management says retention has stayed at historical norms and that new business already signed for 2027 exceeds the prior two selling seasons combined, which supports the pharmacy franchise while it changes models.

    Q2 FY2026 call

  • Regulatory uncertainty around pharmacy benefits has been resolved

    Earlier management described its model as built to flex through regulatory and legislative change; after the FTC settlement and the federal PBM legislation it describes the matter as resolved and its direction as aligned.

    Tone shiftQ3 FY2025 → Q4 FY2025
Bear · 2

  • Drugmaker contracts can be terminated on short notice

    The rebate-free model depends on renegotiated agreements with drug manufacturers, and the company's contracts with them are typically nonexclusive and can be ended quickly by either side.

    10-K, filed 2026-02-26

  • Surprise-billing arbitration is adding cost to the health plan

    Management cited unsustainable volume in the independent dispute resolution process concentrated among a few providers, with most awards favoring providers, which pushes up costs for employers and the plan.

    Q2 FY2026 call